Germline Genetic Testing in Unselected Pancreatic Ductal Adenocarcinoma (PDAC) Patients.
Mary Linton Bounetheau Peters, Randall Brand, Erkut Hasan Borazanci, Lindsey Stobie, Beth Dudley, Eve Karloski, A James Moser, Arlene Colvin, Cynthia Lim, Nathan Bahary, Weijing Sun, John C. Rhee, Barry C. Lembersky, Ronald G. Stoller, Holly LaDuca, Jill S Dolinsky, Emily Dalton, Virginia Speare, Mary Helen Black, Nadine M. Tung; Beth Israel Deaconess Medcl Ctr, Cambridge, MA; University of Pittsburgh, Pittsburgh, PA; HonorHealth/TGen, Scottsdale, AZ; Beth Israel Deaconess Medical Center, Boston, MA; UPMC, Pittsburgh, PA; Honor Health, Scottsdale, AZ; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA; University of Pittsburgh, Division of Hematology-Oncology, Pittsburgh, PA; UPMC CancerCenter, Pittsburgh, PA; Ambry Genetics, Aliso Viejo, CA; Beth Israel Deaconess Medical Center, Dana-Farber Harvard Cancer Center, Boston, MA

Abstract Text:

Background: The aim of this study is to assess the prevalence of known heritable germline mutations in unselected PDAC patients and to determine how well current guidelines for genetic testing identify mutation carriers.

Methods: Consecutive, unselected patients with recently diagnosed PDAC from three centers were enrolled from May to December 2016 in an ongoing prospective study. A three-generation pedigree was obtained. Germline mutations in 12 genes associated with PDAC risk (APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, PALB2, PMS2, STK11, TP53) and in 19 genes related to other cancer risks were screened for by NGS. American College of Gastroenterology and NCCN criteria for genetic testing for BRCA1/2, Lynch syndrome, and Familial Pancreatic Cancer (FPC) were assessed. Results: Among 183 patients, 46% are female, 79% are Caucasian and 10% are Ashkenazi Jewish, with median (IQR) age 68 (62,75) years at diagnosis. 41% of patients met ≥1 criteria for genetic testing (35.5% BRCA1/2, 2.7% Lynch, 9.3% FPC). Twenty patients (11%) were found to have a total of 21 pathogenic mutations (table). Mutation status was not associated with age at diagnosis, sex, or personal history of cancer (all p > 0.05). Six mutation carriers (30% of positives) did not meet current criteria for genetic testing.

Conclusions: Preliminary results show that 6.6% of unselected PDAC patients carry a germline mutation in a gene known to increase PDAC risk and 4.3% have a mutation in genes not previously linked to PDAC. Existing testing criteria did not identify 30% of carriers. Continued refinement of guidelines is necessary to align genetic testing with inherited PDAC risk.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gene</th>
<th>Mutation</th>
<th>Testing Criteria Met</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRCA1/2</td>
</tr>
<tr>
<td>1</td>
<td>ATM</td>
<td>c.1027_1030delGAAA</td>
<td>Y</td>
</tr>
<tr>
<td>2</td>
<td>ATM</td>
<td>c.1564_1565delGA</td>
<td>Y</td>
</tr>
<tr>
<td>3</td>
<td>ATM</td>
<td>c.3245_3247delATCinsTGAT</td>
<td>N</td>
</tr>
<tr>
<td>4</td>
<td>ATM</td>
<td>c.5932G &gt; T</td>
<td>N</td>
</tr>
<tr>
<td>5</td>
<td>ATM</td>
<td>c.6027C &gt; G</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>RAD50</td>
<td>c.1052-2A &gt; C</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>ATM</td>
<td>c.7630-2A &gt; C</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>Gene</td>
<td>Variant Description</td>
<td>Status</td>
</tr>
<tr>
<td>---</td>
<td>----------</td>
<td>-------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>7</td>
<td>BRCA1</td>
<td>c.68_69delAG</td>
<td>Y</td>
</tr>
<tr>
<td>8</td>
<td>BRCA1</td>
<td>c.181T &gt; G</td>
<td>Y</td>
</tr>
<tr>
<td>9</td>
<td>BRCA1</td>
<td>c.5266dupC</td>
<td>Y</td>
</tr>
<tr>
<td>10</td>
<td>BRCA2</td>
<td>c.1237delC</td>
<td>Y</td>
</tr>
<tr>
<td>11</td>
<td>CDKN2A</td>
<td>c.-34G &gt; T</td>
<td>N</td>
</tr>
<tr>
<td>12</td>
<td>CHEK2</td>
<td>c.470T &gt; C</td>
<td>Y</td>
</tr>
<tr>
<td>13</td>
<td>CHEK2</td>
<td>c.470T &gt; C</td>
<td>N</td>
</tr>
<tr>
<td>14</td>
<td>CHEK2</td>
<td>c.470T &gt; C</td>
<td>Y</td>
</tr>
<tr>
<td>15</td>
<td>CHEK2</td>
<td>c.470T &gt; C</td>
<td>Y</td>
</tr>
<tr>
<td>16</td>
<td>CHEK2</td>
<td>c.1116dupC</td>
<td>Y</td>
</tr>
<tr>
<td>17</td>
<td>CHEK2</td>
<td>c.1283C &gt; T</td>
<td>Y</td>
</tr>
<tr>
<td>18</td>
<td>CHEK2</td>
<td>EX8_9del</td>
<td>N</td>
</tr>
<tr>
<td>19</td>
<td>MSH6</td>
<td>c.2230dupG</td>
<td>N</td>
</tr>
<tr>
<td>20</td>
<td>NF1</td>
<td>c.663G &gt; A</td>
<td>N</td>
</tr>
</tbody>
</table>

*No personal or family history of melanoma or other PDAC

**Merit Award Application Material:**

Merit Award Application Materials:

- Letter of Support.pdf (44.1KB) - Letter of Support
- CV Jan 17 2 page.doc (68.0KB) - Curriculum Vitae
Title:
Germline Genetic Testing in Unselected Pancreatic Ductal Adenocarcinoma (PDAC) Patients.

Submitter's E-mail Address:
mbpeters@bidmc.harvard.edu

Is this a late-breaking data submission?
No

Is this abstract a clinical trial?
Yes

Is this clinical trial registered?
Yes

Registry Name:
Clinicaltrials.gov

Registration Number:
NCT02790944

Research Funding Source:
Pharmaceutical/Biotech Company

Research Funding Source Name:
Ambry Genetics

Would like to be considered for a Merit Award:
Yes

Have the data in this abstract been presented at another major medical meeting?
Yes

Meeting:
DDW 2017

Updates to Data:
Early results from the study, focusing on prevalence of mutations, were submitted to DDW. That analysis included 128 patients and described the mutation pattern found among a subset of those patients. The current abstract is expanded to 182 patients with genetic testing results, and covers their eligibility for genetic testing based on national guidelines in addition to prevalence.

Has this research been submitted for publication in a medical journal?
No

Type of Research:
Biomarker

Research Category:
Clinical

Continued Trial Accrual:
Yes

Received Grant funding:
No

Relevant to geriatric oncology:
No

Sponsor:
Nadine M. Tung, MD

First Author
Presenting Author
Corresponding Author
Second Author
Randall Brand, MD
University of Pittsburgh
5200 Centre Ave
Pittsburgh, PA 15232
Phone Number: 412-623-0021
Email: reb53@pitt.edu

Third Author
Erkut Hasan Borazanci, MD
HonorHealth/TGen
Scottsdale, AZ 85254-1044
Alternate Phone: 318-470-9580
Email: Erkut.Borazanci@HonorHealth.com
Alternate Email: mary.mcevoy@honorhealth.com

Fourth Author
Lindsey Stobie, MS, CGC
Beth Israel Deaconess Medical Center
330 Brookline Ave
Boston, MA 02215
Email: lstobie@bidmc.harvard.edu

Fifth Author
Beth Dudley
UPMC
Pittsburgh, PA
Email: dudleyre@upmc.edu

Sixth Author
Eve Karloski
UPMC
Pittsburgh, PA
Email: kalychuke2@upmc.edu

Seventh Author
A James Moser, MD
Beth Israel Deaconess Medical Center
330 Brookline Ave, Stoneman 9
Boston, MA 02215
Phone Number: (617) 667-3746
Email: ajmoser@bidmc.harvard.edu
Fifteenth Author

Holly LaDuca, MS, CGC
Ambry Genetics
Aliso Viejo, CA
Email: HLADUCA@AMBRYGEN.COM

Click to view Conflict of Interest Disclosure

Sixteenth Author

Jill S Dolinsky, MS
Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656
Email: jdolinsky@ambrygen.com

Click to view Conflict of Interest Disclosure

Seventeenth Author

Emily Dalton, MS
Ambry Genetics
Aliso Viejo, CA
Email: edalton@ambrygen.com

Click to view Conflict of Interest Disclosure

Eighteenth Author

Virginia Speare, PhD
Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656
Email: vspeare@ambrygen.com

Click to view Conflict of Interest Disclosure

Nineteenth Author

Mary Helen Black
Ambry Genetics
Aliso Viejo, CA
Email: mblack@ambrygen.com

Click to view Conflict of Interest Disclosure

Twentieth Author

Nadine M. Tung, MD
Beth Israel Deaconess Medical Center, Dana-Farber Harvard Cancer Center
330 Brookline Ave
Boston, MA 02215
Phone Number: (617) 667-7081
Alternate Phone: 508-243-8571
Email: ntung@bidmc.harvard.edu

Click to view Conflict of Interest Disclosure

If necessary, you can make changes to your abstract between now and the deadline of Tuesday, February 7, 2017

- To access your submission in the future, use the direct link to your abstract submission from one of the automatic confirmation emails that were sent to you during the submission.
Or point your browser to /asco/reminder.cgi to have that URL mailed to you again. Your username/password are 184479/703531.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

Tell us what you think of the abstract submission process

Home Page